Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06150898 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt)

Study acronym: KePreSt
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Secondary endpoints: details revised at 2 of 2 entries Site details revised · Eligibility criteria shortened, about 4 words Show 2 more changesShow less
    • Site details revised
    • Eligibility criteria shortened, about 4 words
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Apr 1, 2025 to May 12, 2025 · Study site revised · Eligibility criteria expanded, about 1 wordv4 Show 3 more changesShow less
    • Start date changed from estimate of Apr 1, 2025 to May 12, 2025
    • Study site revised
    • Eligibility criteria expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  3. Primary completion date: Jul 20, 2026 to Apr 20, 2027 Start date: Jan 1, 2025 to Apr 1, 2025 · Completion date: Dec 2026 to Oct 2027 · Interventions: Ketorolac 10 Mg Oral Tablet (Drug), Pregabalin 75mg (Drug), Prospective data and sample collection (Procedure) to Ketorolac 10 Mg Oral Tablet (Drug), Omeprazole 20mg Capsule (Drug), Pregabalin 75mg (Drug), Prospective data and sample collection… · 2 morev3 Show 5 more changesShow less
    • Start date: Jan 1, 2025 to Apr 1, 2025
    • Completion date: Dec 2026 to Oct 2027
    • Interventions: Ketorolac 10 Mg Oral Tablet (Drug), Pregabalin 75mg (Drug), Prospective data and sample collection (Procedure) to Ketorolac 10 Mg Oral Tablet (Drug), Omeprazole 20mg Capsule (Drug), Pregabalin 75mg (Drug), Prospective data and sample collection…
    • Eligibility criteria expanded, about 237 words
    • Site contact updated

    See this version in full on ClinicalTrials.gov ↗

  4. Start date: Feb 20, 2024 to Jan 1, 2025 Collaborators: 2 to 1v2 Show 1 more changeShow less
    • Collaborators: 2 to 1

    See this version in full on ClinicalTrials.gov ↗

  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Out of all proportion to its short duration, the perioperative period is critical in determining the long-term outcome of cancer. To contribute to a better understanding of the neural and inflammatory mechanisms underlying this issue, we aim to implement a novel intervention based on the preoperative use of non-steroidal anti-inflammatory drugs (NSAIDs) with or without an anti-epileptic drug. Our goal is to understand and transform the perioperative window from being a facilitator of metastatic progression to arresting and/or eliminating residual disease using repurposing drugs
Trial Details
NCT Number NCT06150898
Lead Sponsor Jules Bordet Institute
Collaborators: KU Leuven
Conditions Early-stage Breast Cancer, Estrogen-receptor-positive Breast Cancer
Enrollment 112 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov